Yanan Zhu
Stock Analyst at Wells Fargo
(1.71)
# 3,037
Out of 4,827 analysts
75
Total ratings
25.93%
Success rate
-7.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Overweight | $115 → $100 | $35.99 | +177.85% | 2 | May 8, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $75 → $70 | $15.76 | +344.30% | 3 | May 7, 2025 | |
| RGLS Regulus Therapeutics | Downgrades: Equal-Weight | $9 | $7.85 | +14.65% | 2 | May 1, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $2 → $1.5 | $0.30 | +399.83% | 2 | Mar 21, 2025 | |
| AUTL Autolus Therapeutics | Maintains: Overweight | $8 → $6 | $1.42 | +324.03% | 3 | Mar 21, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $25 → $20 | $1.50 | +1,233.33% | 2 | Mar 18, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Overweight | $12 → $10 | - | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $58 → $50 | $10.92 | +357.88% | 6 | Mar 7, 2025 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $5 → $4 | $1.01 | +296.04% | 3 | Mar 6, 2025 | |
| QURE uniQure | Maintains: Equal-Weight | $35 → $30 | $10.32 | +190.70% | 2 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $50 | $7.42 | +573.85% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $5 | $3.78 | +32.28% | 8 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $15 | $0.70 | +2,042.86% | 6 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $7 → $4 | $1.32 | +203.03% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $4 | $0.82 | +387.80% | 4 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $77 | $31.96 | +140.96% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $12.72 | +214.47% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $34.68 | +87.43% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | - | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $25 | $3.12 | +701.28% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $25.99 | +92.38% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.65 | +519.00% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | - | - | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $10 | $1.90 | +427.70% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $546.73 | -40.37% | 1 | Feb 2, 2021 |
Sarepta Therapeutics
May 8, 2025
Maintains: Overweight
Price Target: $115 → $100
Current: $35.99
Upside: +177.85%
Beam Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $15.76
Upside: +344.30%
Regulus Therapeutics
May 1, 2025
Downgrades: Equal-Weight
Price Target: $9
Current: $7.85
Upside: +14.65%
Adaptimmune Therapeutics
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $0.30
Upside: +399.83%
Autolus Therapeutics
Mar 21, 2025
Maintains: Overweight
Price Target: $8 → $6
Current: $1.42
Upside: +324.03%
Metagenomi
Mar 18, 2025
Maintains: Overweight
Price Target: $25 → $20
Current: $1.50
Upside: +1,233.33%
Voyager Therapeutics
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: -
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Maintains: Overweight
Price Target: $58 → $50
Current: $10.92
Upside: +357.88%
Fate Therapeutics
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $5 → $4
Current: $1.01
Upside: +296.04%
uniQure
Feb 28, 2025
Maintains: Equal-Weight
Price Target: $35 → $30
Current: $10.32
Upside: +190.70%
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $50
Current: $7.42
Upside: +573.85%
Feb 24, 2025
Maintains: Equal-Weight
Price Target: $40 → $5
Current: $3.78
Upside: +32.28%
Dec 12, 2024
Maintains: Overweight
Price Target: $20 → $15
Current: $0.70
Upside: +2,042.86%
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $7 → $4
Current: $1.32
Upside: +203.03%
Nov 12, 2024
Maintains: Overweight
Price Target: $17 → $4
Current: $0.82
Upside: +387.80%
Nov 7, 2024
Maintains: Overweight
Price Target: $82 → $77
Current: $31.96
Upside: +140.96%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $12.72
Upside: +214.47%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $34.68
Upside: +87.43%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: -
Upside: -
Mar 1, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $3.12
Upside: +701.28%
Jan 3, 2024
Reiterates: Overweight
Price Target: $50
Current: $25.99
Upside: +92.38%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.65
Upside: +519.00%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: -
Upside: -
Jan 4, 2023
Maintains: Overweight
Price Target: $14 → $10
Current: $1.90
Upside: +427.70%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $546.73
Upside: -40.37%